Sunitinib
Sign in to save this workspacePrimary targets: KDR_VEGFR2 · FDA status: FDA Approved
Selectivity scorecard
KISS
91.73
Gini
0.524
CATDS
0.007
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Sunitinib. Strongest target: CAMK2D at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | CAMK2D | 100.0% | 0.0% |
| 2 | MYLK4 | 99.1% | 0.9% |
| 3 | FLT3 | 98.7% | 1.3% |
| 4 | TNIK | 98.3% | 1.7% |
| 5 | ARK5_NUAK1 | 97.8% | 2.2% |
| 6 | KHS_MAP4K5 | 97.8% | 2.2% |
| 7 | GLK_MAP4K3 | 97.6% | 2.4% |
| 8 | RET | 97.2% | 2.8% |
| 9 | FMS | 97.1% | 2.9% |
| 10 | YES_YES1 | 96.6% | 3.4% |
| 11 | CAMK2A | 96.3% | 3.7% |
| 12 | HPK1_MAP4K1 | 96.3% | 3.7% |
| 13 | AMPK(A2_B2_G2) | 96.3% | 3.7% |
| 14 | LRRK2 | 95.8% | 4.2% |
| 15 | PHKG1 | 95.6% | 4.4% |
| 16 | TRKC | 95.4% | 4.6% |
| 17 | CHK2 | 95.0% | 5.0% |
| 18 | AMPK(A1_B2_G1) | 94.6% | 5.4% |
| 19 | AMPK(A1_B2_G2) | 94.5% | 5.5% |
| 20 | AMPK(A1_B2_G3) | 93.6% | 6.4% |
Selectivity landscape
Where Sunitinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Sunitinib.
Annotations
Sign in to read and post annotations.
Loading…